We found that the ACK1 inhibitor triggered an adaptive autophagy-like response in lung cancer cells, and blocking AMPK or lysosomal degradation increased the cytotoxic effects of ACK1-targeted therapy. This evidence concerns the gene PRKAA1 and lung cancer.